Payment overview · 2025
General Payments
$2,757.66
131 reported records · 22 companies
Healthcare provider profile · identity verified
Mohammed Abbas Ali, M.D.,
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · TAMPA, FL · NPI 1962668574
Verified facts
What the public records show
CMS Open Payments records show Mohammed Abbas Ali, M.D., received $2,757.66 in general payments during 2025 across 131 reported records.
ABBVIE INC. accounted for 14.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OLUMIANT as an associated drug or biological on 560 records involving 277 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Olumiant by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $404.83 | 14.7% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $273.38 | 9.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.91 | 9.1% | 7 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $233.96 | 8.5% | 16 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $216.73 | 7.9% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $204.51 | 7.4% | 9 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $167.62 | 6.1% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $153.03 | 5.5% | 6 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $136.68 | 5.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $120.10 | 4.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.86 | 4.2% | 6 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $104.00 | 3.8% | 8 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $83.59 | 3.0% | 4 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $60.82 | 2.2% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $47.70 | 1.7% | 2 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $42.24 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.64 | 1.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $30.94 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.66 | 0.9% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $18.47 | 0.7% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $18.39 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $15.60 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,657.67 | 130 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $336.82 | 14 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $249.91 | 7 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $233.96 | 16 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $216.73 | 16 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $204.51 | 9 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $167.62 | 6 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $153.03 | 6 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $136.68 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $135.07 | 7 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $120.10 | 5 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $114.86 | 6 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $104.00 | 8 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $100.93 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $88.97 | 4 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $59.28 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $49.34 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $47.70 | 2 | 2025 |
Source payment records
|
|||||
| Yesintek Normalized: yesintek |
Biological | Biocon Biologics Inc | $42.24 | 1 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $40.14 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.64 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $30.94 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | OLUMIANT open payments reported associated product |
CMS Open Payments — General Payments 560 supporting records · 277 recipient NPIs · example record 1186464669 |
Olumiant · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 310 | 89 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 251 | 107 |
| Prednisone | Prednisone | 211 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 33 |
| Gabapentin | Gabapentin | 183 | 86 |
| Methotrexate | Methotrexate Sodium | 165 | 77 |
| Pregabalin | Pregabalin | 124 | 41 |
| Leflunomide | Leflunomide | 119 | 54 |
| Meloxicam | Meloxicam | 90 | 48 |
| Celecoxib | Celecoxib | 84 | 40 |
| Baclofen | Baclofen | 75 | 39 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 62 | 22 |
| Topiramate | Topiramate | 61 | 25 |
| Allopurinol | Allopurinol | 53 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 22 |
| Folic Acid | Folic Acid | 49 | 22 |
| Humira(Cf) Pen | Adalimumab | 47 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 45 | suppressed |
| Rinvoq | Upadacitinib | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 15 |
| Leucovorin Calcium | Leucovorin Calcium | 31 | 15 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Olumiant | Baricitinib | 30 | suppressed |
| Enbrel Mini | Etanercept | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Lisinopril | Lisinopril | 25 | suppressed |
| Azathioprine | Azathioprine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Actemra Actpen | Tocilizumab | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Enbrel Sureclick | Etanercept | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Orencia Clickject | Abatacept | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,757.66 · 131 records | ABBVIE INC. | ACTHAR, BENLYSTA, Bimzelx, CRYSVITA, EVENITY, Gazyva, HADLIMA, HYRIMOZ, INSPIRE, Kineret, LUPKYNIS, NEXPLANON, OTEZLA, PURIFIED CORTROPHIN GEL, RENFLEXIS, RINVOQ, SAPHNELO, SKYRIZI, SMARTVEST, TALTZ, TAVNEOS, TONMYA, TREMFYA, Tyenne, Tymlos, XELJANZ, Yesintek, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rinvoq play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error